Results 11 to 20 of about 22,830 (226)

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization [PDF]

Archives of Pathology & Laboratory Medicine, 2019
Context.— The ability to determine ROS1 status has become mandatory for patients with lung adenocarcinoma, as many global authorities have approved crizotinib for patients with ROS1-positive lung adenocarcinoma. Objective.— To present ...
Huang, Richard, Smith, Derek, Le, Catherine, Liu, Wen-Wei, Ordinario, Ellen, Manohar, Chitra, Lee, Michael, Rajamani, Jaya, Truong, Huan, Li, Jing, Choi, Cindy, Li, Jingchuan, Pati, Amrita, Bubendorf, Lukas, Buettner, Reinhard, Kerr, Keith, Lopez-Rios, Fernando, Marchetti, Antonio, Marondel, Ivonne, Nicholson, Andrew, Öz, Ayşim Büge, Pauwels, Patrick, Penault-Llorca, Frédérique, Rossi, Giulio, Thunnissen, Erik, Newell, Amy Hanlon, Pate, Greg, Menzl, Ina   +27 more
core   +7 more sources

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

Thoracic Cancer, 2023
Background The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1
Tara L. Peters, Nan Chen, Logan C. Tyler, Anh T. Le, Anastasios Dimou, Robert C. Doebele   +5 more
doaj   +2 more sources

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain [PDF]

BMC Cancer, 2022
Background Detection of the ROS1 rearrangement is mandatory in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to allow targeted therapy with specific inhibitors. However, in Spanish clinical practice ROS1 determination is not yet
Federico Rojo, Esther Conde, Héctor Torres, Luis Cabezón-Gutiérrez, Dolores Bautista, Inmaculada Ramos, David Carcedo, Natalia Arrabal, J. Francisco García, Raquel Galán, Ernest Nadal   +10 more
doaj   +3 more sources

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma

JTO Clinical and Research Reports, 2023
Introduction: Translocations of the ROS1 gene were found to drive tumorigenesis in 1% to 2% of lung adenocarcinoma. In clinical practice, ROS1 rearrangements are often screened by immunohistochemistry (IHC) before confirmation with either fluorescence in
Karl Grenier, MD, PhD, Jean-Baptiste Rivière, PhD, Bouchra Ouled Amar Bencheikh, PhD, Andrea Liliam Gomez Corredor, PhD, Benjamin Christopher Shieh, MD, Hangjun Wang, MD, Pierre Olivier Fiset, MD, PhD, Sophie Camilleri-Broët, MD, PhD   +7 more
doaj   +2 more sources

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition [PDF]

npj Precision Oncology, 2020
AbstractHistologic transformation from non-small cell to small cell lung cancer has been reported as a resistance mechanism to targeted therapy in EGFR-mutant and ALK fusion-positive lung cancers. Whether small cell transformation occurs in other oncogene-driven lung cancers remains unknown.
Jessica J. Lin, Adam Langenbucher, Pranav Gupta, Satoshi Yoda, Isobel J. Fetter, Marguerite Rooney, Andrew Do, Marina Kem, Kylie Prutisto Chang, Audris Y. Oh, Emily Chin, Dejan Juric, Ryan B. Corcoran, Ibiayi Dagogo-Jack, Justin F. Gainor, James R. Stone, Jochen K. Lennerz, Michael S. Lawrence, Aaron N. Hata, Mari Mino-Kenudson, Alice T. Shaw   +20 more
openaire   +4 more sources

Molecular and Clinical characteristics of ROS1 Fusion Variants in ROS1-rearranged Cancers: A Defined Role of Fusion Partners and Breakpoints of ROS1 [PDF]

European Journal of Cancer
ROS1-targeted tyrosine kinase inhibitors (TKIs) are the standard treatment for ROS1-rearranged cancers. We here investigated the therapeutic significance of multiple fusion partners and variable ROS1 genomic breakpoints.We retrieved 81 ROS1-rearranged cases from a clinical DNA-based next generation sequencing cohort and performed comprehensive analyses,
Jeong, J.-S., Shin, Y., Yoon, S., Kim, D., Sampson, J., Bayliss, R., Choi, J.   +6 more
openaire   +4 more sources

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers [PDF]

npj Precision Oncology
Abstract Purpose Despite the robust efficacy of ROS1 tyrosine kinase inhibitors (TKIs) in ROS1-positive non-small cell lung cancer, TKI resistance continues to hamper durability of the therapeutic response. The resistance liabilities of next-generation ROS1 TKI are sparsely characterized.
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z. Beach, Guilherme Harada, Alexander Drilon, Monika A. Davare   +9 more
openaire   +6 more sources

ROS1-Rearranged Lung Adenocarcinoma: From Molecular Genetics to Target Therapy

Onco, 2023
Non-small-cell lung cancer (NSCLC) is a heterogeneous group of diseases accounting for 80–85% of lung cancers. A molecular subset of NSCLC (1–2.5%) harboring molecular rearrangements of the tyrosine kinase gene ROS1 is defined as ROS1-positive and is ...
Ugo Testa, Germana Castelli, Elvira Pelosi   +2 more
doaj   +2 more sources

ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. [PDF]

, 2022
c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of ROS1 ...
Markus Rechsteiner, Ralph M. Fritsch, Christian Britschgi, Ethan Sokol, Abdullah Kahraman, Hussung, Saskia, Fabian Arnold, Britschgi, Christian, Moch, Holger, Sivakumar, Smruthy, Arnold, Fabian, Smruthy Sivakumar, Saskia Hussung, Sokol, Ethan, Dilara Akhoundova, Rechsteiner, Markus, Angst, Florian, Fritsch, Ralph M., Zoche, Martin, Antonia Töpfer, Akhoundova, Dilara, Töpfer, Antonia, Achim Weber, Weber, Achim, Fritsch, Ralph M, Kahraman, Abdullah, Florian Angst, Martin Zoche, Holger Moch   +28 more
core   +2 more sources

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas [PDF]

American Journal of Surgical Pathology, 2013
ROS1 gene rearrangements are reported in 1% to 2% of lung adenocarcinomas (ACAs) and are associated with response to the multitargeted tyrosine kinase inhibitor crizotinib. ROS1 rearrangements can be detected using fluorescence in situ hybridization (FISH); however, immunohistochemistry (IHC) for ROS1 protein is a promising alternate screening modality.
Sholl, Lynette, Sun, Heather, Butaney, Mohit, Zhang, Chengsheng, Lee, Charles, Janne, Pasi, Rodig, Scott   +6 more
openaire   +4 more sources